Text Size:

What is the history of Mumps vaccine use in America?


vaccine history

The mumps virus was detected in 1934, and isolated in 1945, however it took researchers until 1948 to grow the virus in a laboratory setting.1 The first mumps vaccine, a killed virus vaccine, was developed for use in the United States in 1948.2 This vaccine, producing only short-term immunity, was available and used from 1950 until its discontinuation in 1978.3

In 1963, vaccine researcher Maurice Hilleman used samples from his own daughter’s mumps case to isolate the mumps virus.4 This mumps strain, known as the Jeryl Lyn Strain named for his daughter, was used to create Mumpsvax, the first live mumps virus vaccine.5 Mumpsvax, manufactured by Merck, became available for use in the United States in 1967.6  In 1971, Mumpsvax was combined with the measles and rubella vaccine to become the MMR vaccine.7 Currently, mumps vaccine is only available in combination with measles and rubella (MMRII)8 and measles, rubella, and varicella (ProQuad)9. Both vaccines are manufactured by Merck.

In 1977, the CDC’s Advisory Committee on Immunization Practices (ACIP) recommended a single dose of mumps vaccine for all children at 12 months of age.10 However, in response to a resurgence of measles in the United States in 1989, the ACIP updated its recommendation, recommending that two doses of a measles containing vaccine, preferably the MMR vaccine, be administered to all children. In this recommendation, the ACIP acknowledged that mumps outbreaks have occurred in highly vaccinated populations and that an additional dose of mumps vaccine was important to assure immunity, however, there was no formal recommendation for a second dose of mumps vaccine to be administered.11 Recommendations were updated again in 1998 when the ACIP recommended that the MMR vaccine be the vaccine of choice and for all fifty states to adopt vaccine legislation requiring that children receive two doses of MMR vaccine, after the age of 12 months, and at least one month apart, for school entry.12 At the time of this recommendation, the ACIP did not consider the second dose of MMR vaccine to be a booster dose for mumps or rubella, reporting “a primary immune response to the first dose provides long-term protection.”13 They did, however, report that field studies on the mumps vaccine indicated an estimated vaccine effectiveness to be between 75 and 95 percent.14

Mumps infections in the U.S. remained low until late 2005, when the Midwest experienced a large outbreak in a highly vaccinated population that included several college campuses.15 16 As a result of this outbreak, the ACIP formally recommended two doses of mumps vaccine for school aged children and high-risk adults in May 2006.17  High-risk adults were defined as college students, health care providers, and international travelers.18  Mumps outbreaks continued to occur both in the United States as well as abroad.19 20 21 22

In 2010, two former Merck employees filed a lawsuit alleging that Merck altered testing and study results to make the mumps vaccine appear more effective than it is in preventing mumps in children. The lawsuit, unsealed in 2012, also claimed that outbreaks in vaccinated populations were directly related to the falsification of the mumps efficacy data.

Specifically, the suit claims Merck manipulated the results of clinical trials beginning in the late 1990s so as to be able to report that the combined mumps vaccine, known as MMR-II (a revised version of the 1971 MMR shot containing a different strain of the rubella virus), is 95 percent effective, in an effort to maintain its exclusive license to manufacture it. This percentage is the benchmark used by the FDA to grant Merck approval to sell its original mumps vaccine in 1967.”23

Scientists involved in the whistleblower case claimed that Merck falsified vaccine efficacy testing by adding animal antibodies to the samples in order to demonstrate a vaccine effectiveness of 95 percent.24

Merck denied all charges in connection with the lawsuit and stated:

"Merck has presented information that demonstrated to the United States Department of Justice that these allegations are factually false and after the department conducted its own two-year investigation, it decided not to pursue this lawsuit."25

In 2015, Merck was accused by attorneys representing the scientists of stonewalling the case by stating that they are unable to perform current clinical trials of the mumps vaccine to determine current efficacy of the vaccine and instead provided the court with 50-year old efficacy data.26Trial proceedings in the case were expected to begin in 2018, however, was delayed until late 2019.

In 2017, as a result of continued outbreaks in fully vaccinated populations, the CDC’s Advisory Committee of Immunization Practices (ACIP) recommended that a third dose of a mumps containing vaccine be administered in the event of an outbreak, stating:

“Current routine recommendation for 2 doses of MMR vaccine appears to be sufficient for mumps control in the general population, but insufficient for preventing mumps outbreaks in prolonged, close-contact settings, even where coverage with 2 doses of MMR vaccine is high.”27

IMPORTANT NOTE: NVIC encourages you to become fully informed about Mumps and the Mumps vaccine by reading all sections in the Table of Contents, which contain many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.

« Return to Vaccines & Diseases Table of Contents

References

1 CDC. Mumps - Mumps Vaccine Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book). 13th ed. 2015.

2 Ibid

3 CDC Recommendation of the Immunization Practices Advisory Committee Mumps Vaccine MMWR 31(46);617-20,625-7

4 Conniff, R A Forgotten Pioneer of Vaccines. The New York Times. May 6, 2013

5Mumpsvax vaccine product insert advertisement. C.M.A. Journal May 23, 1970; Vol. 102 (1015)

6 Merck Over 100 years of developing vaccines*. May 2017

7 Ibid

8 FDA Measles, Mumps and Rubella Virus Vaccine, Live  May 16, 2017

9 FDA PROQUAD. May 16, 2017

10 CDC Recommendations of the Immunization Practices Advisory Committee Mumps Prevention. MMWR Jun 9, 1989. 38(22);388-392,397-400

11 CDC Measles Prevention: Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR. Dec. 29, 1989; 38(S-9);1-18

12 CDC Measles, Mumps, and Rubella -- Vaccine Use and Strategies for Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of Mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR. May 22, 1998; 47(RR-8);1-57

13 Ibid

14 Ibid

15 CDC. Mumps Epidemic --- Iowa, 2006. MMWR Apr. 7, 2006; 55(13);366-368

16 CDC Update: Multistate Outbreak of Mumps --- United States, January 1--May 2, 2006. MMWR. May 26, 2006; 55(20);559-563

17 CDC Notice to Readers: Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP) for the Control and Elimination of Mumps. MMWR. June 9, 2006; 55(22);629-630

18 Ibid

19 CDC Update: Mumps Outbreak --- New York and New Jersey, June 2009--January 2010 MMWR Feb. 12, 2010; 59(05);125-129

20 CDC Mumps Outbreak --- New York, New Jersey, Quebec, 2009 Nov. 12, 2009; 58;1-4

21 Choi KM. Reemergence of mumps. Korean J Pediatr. 2010 May; 53(5): 623–628.

22 Dayan GH, Quinlisk MP, Parker AA et al. Recent resurgence of mumps in the United States. N Engl J Med. 2008 Apr 10;358(15):1580-9.

23 Koleva G, Merck Whistleblower Suit A Boon to Vaccine Foes Even As It Stresses Importance of Vaccines. Forbes. Jun. 27, 2012.

24 Pierson M. Merck accused of stonewalling in mumps vaccine antitrust lawsuit. Reuters. Jun 4, 2015

25 Mulder JT. Syracuse University mumps outbreak: Whistleblowers say vaccine is flawed. Syracuse.com. Nov. 14, 2017

26 Pierson M. Merck accused of stonewalling in mumps vaccine antitrust lawsuit. Reuters. Jun 4, 2015

27 CDC Recommendation of the Advisory Committee on Immunization Practices for Use of a Third Dose of Mumps Virus–Containing Vaccine in Persons at Increased Risk for Mumps During an Outbreak. MMWR Jan. 12, 2018;67(1);33–38


Make a Difference Support NVIC

NVIC is 100% funded by donations.
Please give.

Help educate families about preventing vaccine injury and death by donating to NVIC today.

Discover How You Can Take Action to Support Our Efforts

Support NVIC!


Connect with us!

  • NVIC Pinterest
  • NVIC Facebook
  • NVIC Twitter
  • NVIC Youtube
  • NVIC Instagram

Ask 8 Kiosk & Educational Marketplace

Ask 8 Questions

Visit our Ask 8 Kiosk to explore a variety of FREE educational materials, from posters and brochures to embeddable web graphics and other resources.

View FREE Downloads